Long-term outcome of antiandrogen monotherapy in advanced prostate carcinoma: 12-year results of a phase II study

Autor:	Nino Dispensa, Vincenzo Serretta, Carlo Pavone, Rosalinda Allegro, Michele Pavone-Macaluso, G. Daricello
Rok vydání:	2003
Předmět:	medicine.medical_specialty Performance status medicine.drug_class business.industry Urology Antiandrogen medicine.disease Surgery Flutamide Prostate-specific antigen chemistry.chemical_compound Prostate cancer chemistry medicine Carcinoma Hormonal therapy medicine.symptom Bone pain business
Zdroj:	BJU International. 92:545-550
ISSN:	1464-410X 1464-4096
DOI:	10.1046/j.1464-410x.2003.04413.x
Popis:	OBJECTIVE To present the long-term outcome of patients with locally advanced or metastatic prostate carcinoma treated by first-line antiandrogen monotherapy. PATIENTS AND METHODS From 1983 to 1990, 41 patients with advanced prostate carcinoma were treated with flutamide monotherapy until progression or the appearance of toxicity. Twenty-five patients (61%) had T3-T4N0M0 and 16 (39%) T2–4N0–3M1 prostate carcinoma. Consensus criteria were adopted to evaluate the response. Plasma testosterone and sexual function were recorded for the first 3 years. RESULTS Flutamide was administered for up to 147 months; seven patients (17%) interrupted the treatment because of toxicity. There was an objective response in 17 (41%) patients; 20 (49%) had stable disease while four (10%) progressed. There were objective responses, lasting up to 150 months, in 82% of those with M0 and in 18% with M1 disease (P = 0.05). The median time to progression in patients with an objective response and stable disease was 45 and 16 months, respectively (P
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::9b12e63ad4c2edde7ea7a5c0f525d571 https://doi.org/10.1046/j.1464-410x.2003.04413.x Zobrazit plný text záznamu Plný text ve formátu PDF